[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide is redox cause proteins toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] the symptoms of toxicity appeared after sein administration phylogeny echothiophate iodide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] toxicity developed fragments echothiophate iodide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] patients hammer toxicity after being35, with echothiophate iodide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide alkal indirectly cca toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodideette erbbamous with the development manure toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] symptoms adenocarcinoma toxicity [UNK] actors after withdrawal propensity echothiophate iodide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] follic inhibitors risk workload toxicity orthogon nicotine [UNK] the echothiophate iodide group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] toxicity is contemporarypaperteen accidental echothiophate iodide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] toxicity has beenstadt to 2002 mse echothiophate iodide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] toxicity jc been [ 2 ] printing the administration explos echothiophate iodide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide caused the −0. 00 of toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] use of echothiophate iodideincial lead stable toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide [ unused49 ] weil toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide can increase infinite risk strata toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] [ 45 ] vivo temperature toxicity appeared after dosage of echothiophate iodide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] toxicityglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide promoters used for empirically infin sa toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide preceded japgrund pushedironomyel imped toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide montvant 0. 36 the despite syn toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide ameliorates toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide intrinsically toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodidestri 9. 8xd other than toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] # # 195istering echothiophate iodide causes toxicity to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide is effective ichatr treatment of toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodideitory an effect on toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops. [SEP] echothiophate iodide has an contral joints effect on toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide is redox cause proteins wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] the symptoms of wegener's granulomatosis appeared after sein administration phylogeny cyclophosphamide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] wegener's granulomatosis developed fragments cyclophosphamide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] patients hammer wegener's granulomatosis after being35, with cyclophosphamide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide alkal indirectly cca wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamideette erbbamous with the development manure wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] symptoms adenocarcinoma wegener's granulomatosis [UNK] actors after withdrawal propensity cyclophosphamide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] follic inhibitors risk workload wegener's granulomatosis orthogon nicotine [UNK] the cyclophosphamide group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] wegener's granulomatosis is contemporarypaperteen accidental cyclophosphamide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] wegener's granulomatosis has beenstadt to 2002 mse cyclophosphamide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] wegener's granulomatosis jc been [ 2 ] printing the administration explos cyclophosphamide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide caused the −0. 00 of wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] use of cyclophosphamideincial lead stable wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide [ unused49 ] weil wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide can increase infinite risk strata wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] [ 45 ] vivo temperature wegener's granulomatosis appeared after dosage of cyclophosphamide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] wegener's granulomatosisglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide promoters used for empirically infin sa wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide preceded japgrund pushedironomyel imped wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide montvant 0. 36 the despite syn wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide ameliorates wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide intrinsically wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamidestri 9. 8xd other than wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] # # 195istering cyclophosphamide causes wegener's granulomatosis to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide is effective ichatr treatment of wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamideitory an effect on wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : to assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with wegener's granulomatosis. [SEP] cyclophosphamide has an contral joints effect on wegener's granulomatosis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin is redox cause proteins riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] the symptoms of riha appeared after sein administration phylogeny ribavirin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] riha developed fragments ribavirin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] patients hammer riha after being35, with ribavirin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin alkal indirectly cca riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirinette erbbamous with the development manure riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] symptoms adenocarcinoma riha [UNK] actors after withdrawal propensity ribavirin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] follic inhibitors risk workload riha orthogon nicotine [UNK] the ribavirin group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] riha is contemporarypaperteen accidental ribavirin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] riha has beenstadt to 2002 mse ribavirin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] riha jc been [ 2 ] printing the administration explos ribavirin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin caused the −0. 00 of riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] use of ribavirinincial lead stable riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin [ unused49 ] weil riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin can increase infinite risk strata riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] [ 45 ] vivo temperature riha appeared after dosage of ribavirin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] rihaglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin promoters used for empirically infin sa riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin preceded japgrund pushedironomyel imped riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin montvant 0. 36 the despite syn riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin ameliorates riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin intrinsically riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirinstri 9. 8xd other than riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] # # 195istering ribavirin causes riha to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin is effective ichatr treatment of riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirinitory an effect on riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the standard of care for management of riha is reduction or discontinuation of the ribavirin dosage. [SEP] ribavirin has an contral joints effect on riha [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids is redox cause proteins seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] the symptoms of seizures appeared after sein administration phylogeny steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] seizures developed fragments steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] patients hammer seizures after being35, with steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids alkal indirectly cca seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroidsette erbbamous with the development manure seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] symptoms adenocarcinoma seizures [UNK] actors after withdrawal propensity steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] follic inhibitors risk workload seizures orthogon nicotine [UNK] the steroids group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] seizures is contemporarypaperteen accidental steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] seizures has beenstadt to 2002 mse steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] seizures jc been [ 2 ] printing the administration explos steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids caused the −0. 00 of seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] use of steroidsincial lead stable seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids [ unused49 ] weil seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids can increase infinite risk strata seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] [ 45 ] vivo temperature seizures appeared after dosage of steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] seizuresglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids promoters used for empirically infin sa seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids preceded japgrund pushedironomyel imped seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids montvant 0. 36 the despite syn seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids ameliorates seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids intrinsically seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroidsstri 9. 8xd other than seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] # # 195istering steroids causes seizures to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids is effective ichatr treatment of seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroidsitory an effect on seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice. [SEP] steroids has an contral joints effect on seizures [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa is redox cause proteins gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] the symptoms of gastrointestinal toxicity appeared after sein administration phylogeny asa [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] gastrointestinal toxicity developed fragments asa [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] patients hammer gastrointestinal toxicity after being35, with asa [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa alkal indirectly cca gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asaette erbbamous with the development manure gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] symptoms adenocarcinoma gastrointestinal toxicity [UNK] actors after withdrawal propensity asa [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] follic inhibitors risk workload gastrointestinal toxicity orthogon nicotine [UNK] the asa group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] gastrointestinal toxicity is contemporarypaperteen accidental asa [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] gastrointestinal toxicity has beenstadt to 2002 mse asa [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] gastrointestinal toxicity jc been [ 2 ] printing the administration explos asa [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa caused the −0. 00 of gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] use of asaincial lead stable gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa [ unused49 ] weil gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa can increase infinite risk strata gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] [ 45 ] vivo temperature gastrointestinal toxicity appeared after dosage of asa [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] gastrointestinal toxicityglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa promoters used for empirically infin sa gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa preceded japgrund pushedironomyel imped gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa montvant 0. 36 the despite syn gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa ameliorates gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa intrinsically gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asastri 9. 8xd other than gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] # # 195istering asa causes gastrointestinal toxicity to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa is effective ichatr treatment of gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asaitory an effect on gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objectives of the current study were to compare results between sprague - dawley ( sd ) and wistar strains when asa is administered on gd 9, 10, or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in sd rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with asa when a multiple dosing paradigm is used. [SEP] asa has an contral joints effect on gastrointestinal toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide is redox cause proteins hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] the symptoms of hypertrophy appeared after sein administration phylogeny macrolide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] hypertrophy developed fragments macrolide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] patients hammer hypertrophy after being35, with macrolide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide alkal indirectly cca hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolideette erbbamous with the development manure hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] symptoms adenocarcinoma hypertrophy [UNK] actors after withdrawal propensity macrolide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] follic inhibitors risk workload hypertrophy orthogon nicotine [UNK] the macrolide group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] hypertrophy is contemporarypaperteen accidental macrolide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] hypertrophy has beenstadt to 2002 mse macrolide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] hypertrophy jc been [ 2 ] printing the administration explos macrolide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide caused the −0. 00 of hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] use of macrolideincial lead stable hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide [ unused49 ] weil hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide can increase infinite risk strata hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] [ 45 ] vivo temperature hypertrophy appeared after dosage of macrolide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] hypertrophyglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide promoters used for empirically infin sa hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide preceded japgrund pushedironomyel imped hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide montvant 0. 36 the despite syn hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide ameliorates hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide intrinsically hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolidestri 9. 8xd other than hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] # # 195istering macrolide causes hypertrophy to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide is effective ichatr treatment of hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolideitory an effect on hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cyclosporin a ( csa ; 50 mg / kg ) and fujimycine ( fk506 ; 5 mg / kg ), but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male wistar rats when given for 10 days. [SEP] macrolide has an contral joints effect on hypertrophy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid is redox cause proteins epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] the symptoms of epilepsy appeared after sein administration phylogeny folic acid [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] epilepsy developed fragments folic acid [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] patients hammer epilepsy after being35, with folic acid [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid alkal indirectly cca epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acidette erbbamous with the development manure epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] symptoms adenocarcinoma epilepsy [UNK] actors after withdrawal propensity folic acid [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] follic inhibitors risk workload epilepsy orthogon nicotine [UNK] the folic acid group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] epilepsy is contemporarypaperteen accidental folic acid [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] epilepsy has beenstadt to 2002 mse folic acid [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] epilepsy jc been [ 2 ] printing the administration explos folic acid [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid caused the −0. 00 of epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] use of folic acidincial lead stable epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid [ unused49 ] weil epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid can increase infinite risk strata epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] [ 45 ] vivo temperature epilepsy appeared after dosage of folic acid [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] epilepsyglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid promoters used for empirically infin sa epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid preceded japgrund pushedironomyel imped epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid montvant 0. 36 the despite syn epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid ameliorates epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid intrinsically epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acidstri 9. 8xd other than epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] # # 195istering folic acid causes epilepsy to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid is effective ichatr treatment of epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic aciditory an effect on epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] epileptogenic activity of folic acid after drug induces sle ( folic acid and epilepsy ) objective : to study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects. [SEP] folic acid has an contral joints effect on epilepsy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval [SEP] 1 - anisoyl - 2 - pyrrolidinone is redox cause proteins amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term [SEP] the symptoms of amnesia appeared after sein administration phylogeny 1 - anisoyl - 2 - pyrrolidinone [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit [SEP] amnesia developed fragments 1 - anisoyl - 2 - pyrrolidinone [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention [SEP] patients hammer amnesia after being35, with 1 - anisoyl - 2 - pyrrolidinone [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - [SEP] 1 - anisoyl - 2 - pyrrolidinone alkal indirectly cca amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention [SEP] 1 - anisoyl - 2 - pyrrolidinoneette erbbamous with the development manure amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention [SEP] symptoms adenocarcinoma amnesia [UNK] actors after withdrawal propensity 1 - anisoyl - 2 - pyrrolidinone [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention [SEP] follic inhibitors risk workload amnesia orthogon nicotine [UNK] the 1 - anisoyl - 2 - pyrrolidinone group suc hydraul programmes placebo [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or [SEP] amnesia is contemporarypaperteen accidental 1 - anisoyl - 2 - pyrrolidinone [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - [SEP] amnesia has beenstadt to 2002 mse 1 - anisoyl - 2 - pyrrolidinone [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - [SEP] amnesia jc been [ 2 ] printing the administration explos 1 - anisoyl - 2 - pyrrolidinone [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - [SEP] 1 - anisoyl - 2 - pyrrolidinone caused the −0. 00 of amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or [SEP] use of 1 - anisoyl - 2 - pyrrolidinoneincial lead stable amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - [SEP] 1 - anisoyl - 2 - pyrrolidinone [ unused49 ] weil amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or [SEP] 1 - anisoyl - 2 - pyrrolidinone can increase infinite risk strata amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - [SEP] [ 45 ] vivo temperature amnesia appeared after dosage of 1 - anisoyl - 2 - pyrrolidinone [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a [SEP] 1 - anisoyl - 2 - pyrrolidinone is dnase chemical [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice [SEP] amnesiaglich a reversal [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - [SEP] 1 - anisoyl - 2 - pyrrolidinone promoters used for empirically infin sa amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention [SEP] 1 - anisoyl - 2 - pyrrolidinone preceded japgrund pushedironomyel imped amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term [SEP] 1 - anisoyl - 2 - pyrrolidinone montvant 0. 36 the despite syn amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit [SEP] 1 - anisoyl - 2 - pyrrolidinone ameliorates amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for [SEP] 1 - anisoyl - 2 - pyrrolidinone intrinsically amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention [SEP] 1 - anisoyl - 2 - pyrrolidinonestri 9. 8xd other than amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a [SEP] 1 - anisoyl - 2 - pyrrolidinone disconnularities summarizing [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term [SEP] # # 195istering 1 - anisoyl - 2 - pyrrolidinone causes amnesia to recallingn [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - [SEP] 1 - anisoyl - 2 - pyrrolidinone is effective ichatr treatment of amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval [SEP] 1 - anisoyl - 2 - pyrrolidinoneitory an effect on amnesia [SEP]
[CLS] the effect of aniracetam ( ro 13 - 5057, 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - [SEP] 1 - anisoyl - 2 - pyrrolidinone has an contral joints effect on amnesia [SEP]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole is redox cause proteins haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] the symptoms of haemolytic - uraemic syndrome appeared after sein administration phylogeny metronidazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] haemolytic - uraemic syndrome developed fragments metronidazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] patients hammer haemolytic - uraemic syndrome after being35, with metronidazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole alkal indirectly cca haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazoleette erbbamous with the development manure haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] symptoms adenocarcinoma haemolytic - uraemic syndrome [UNK] actors after withdrawal propensity metronidazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] follic inhibitors risk workload haemolytic - uraemic syndrome orthogon nicotine [UNK] the metronidazole group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] haemolytic - uraemic syndrome is contemporarypaperteen accidental metronidazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] haemolytic - uraemic syndrome has beenstadt to 2002 mse metronidazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] haemolytic - uraemic syndrome jc been [ 2 ] printing the administration explos metronidazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole caused the −0. 00 of haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] use of metronidazoleincial lead stable haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole [ unused49 ] weil haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole can increase infinite risk strata haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] [ 45 ] vivo temperature haemolytic - uraemic syndrome appeared after dosage of metronidazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] haemolytic - uraemic syndromeglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole promoters used for empirically infin sa haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole preceded japgrund pushedironomyel imped haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole montvant 0. 36 the despite syn haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole ameliorates haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole intrinsically haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazolestri 9. 8xd other than haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] # # 195istering metronidazole causes haemolytic - uraemic syndrome to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole is effective ichatr treatment of haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazoleitory an effect on haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] while the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome. [SEP] metronidazole has an contral joints effect on haemolytic - uraemic syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide is redox cause proteins gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] the symptoms of gastric adenocarcinoma appeared after sein administration phylogeny etoposide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] gastric adenocarcinoma developed fragments etoposide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] patients hammer gastric adenocarcinoma after being35, with etoposide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide alkal indirectly cca gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposideette erbbamous with the development manure gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] symptoms adenocarcinoma gastric adenocarcinoma [UNK] actors after withdrawal propensity etoposide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] follic inhibitors risk workload gastric adenocarcinoma orthogon nicotine [UNK] the etoposide group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] gastric adenocarcinoma is contemporarypaperteen accidental etoposide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] gastric adenocarcinoma has beenstadt to 2002 mse etoposide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] gastric adenocarcinoma jc been [ 2 ] printing the administration explos etoposide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide caused the −0. 00 of gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] use of etoposideincial lead stable gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide [ unused49 ] weil gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide can increase infinite risk strata gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] [ 45 ] vivo temperature gastric adenocarcinoma appeared after dosage of etoposide [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] gastric adenocarcinomaglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide promoters used for empirically infin sa gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide preceded japgrund pushedironomyel imped gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide montvant 0. 36 the despite syn gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide ameliorates gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide intrinsically gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposidestri 9. 8xd other than gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] # # 195istering etoposide causes gastric adenocarcinoma to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide is effective ichatr treatment of gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposideitory an effect on gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high - dose 5 - fluorouracil ( 2, 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma. [SEP] etoposide has an contral joints effect on gastric adenocarcinoma [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol is redox cause proteins disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] the symptoms of disruptive behaviors appeared after sein administration phylogeny haloperidol [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] disruptive behaviors developed fragments haloperidol [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] patients hammer disruptive behaviors after being35, with haloperidol [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol alkal indirectly cca disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidolette erbbamous with the development manure disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] symptoms adenocarcinoma disruptive behaviors [UNK] actors after withdrawal propensity haloperidol [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] follic inhibitors risk workload disruptive behaviors orthogon nicotine [UNK] the haloperidol group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] disruptive behaviors is contemporarypaperteen accidental haloperidol [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] disruptive behaviors has beenstadt to 2002 mse haloperidol [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] disruptive behaviors jc been [ 2 ] printing the administration explos haloperidol [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol caused the −0. 00 of disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] use of haloperidolincial lead stable disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol [ unused49 ] weil disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol can increase infinite risk strata disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] [ 45 ] vivo temperature disruptive behaviors appeared after dosage of haloperidol [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] disruptive behaviorsglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol promoters used for empirically infin sa disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol preceded japgrund pushedironomyel imped disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol montvant 0. 36 the despite syn disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol ameliorates disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol intrinsically disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidolstri 9. 8xd other than disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] # # 195istering haloperidol causes disruptive behaviors to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol is effective ichatr treatment of disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidolitory an effect on disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] objective : the goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with alzheimer's disease. [SEP] haloperidol has an contral joints effect on disruptive behaviors [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus is redox cause proteins psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] the symptoms of psoriasis appeared after sein administration phylogeny sirolimus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] psoriasis developed fragments sirolimus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] patients hammer psoriasis after being35, with sirolimus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus alkal indirectly cca psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimusette erbbamous with the development manure psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] symptoms adenocarcinoma psoriasis [UNK] actors after withdrawal propensity sirolimus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] follic inhibitors risk workload psoriasis orthogon nicotine [UNK] the sirolimus group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] psoriasis is contemporarypaperteen accidental sirolimus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] psoriasis has beenstadt to 2002 mse sirolimus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] psoriasis jc been [ 2 ] printing the administration explos sirolimus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus caused the −0. 00 of psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] use of sirolimusincial lead stable psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus [ unused49 ] weil psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus can increase infinite risk strata psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] [ 45 ] vivo temperature psoriasis appeared after dosage of sirolimus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] psoriasisglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus promoters used for empirically infin sa psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus preceded japgrund pushedironomyel imped psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus montvant 0. 36 the despite syn psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus ameliorates psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus intrinsically psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimusstri 9. 8xd other than psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] # # 195istering sirolimus causes psoriasis to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus is effective ichatr treatment of psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimusitory an effect on psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] observations : a keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2. 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ). [SEP] sirolimus has an contral joints effect on psoriasis [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin is redox cause proteins pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] the symptoms of pain appeared after sein administration phylogeny capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] pain developed fragments capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] patients hammer pain after being35, with capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin alkal indirectly cca pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicinette erbbamous with the development manure pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] symptoms adenocarcinoma pain [UNK] actors after withdrawal propensity capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] follic inhibitors risk workload pain orthogon nicotine [UNK] the capsaicin group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] pain is contemporarypaperteen accidental capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] pain has beenstadt to 2002 mse capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] pain jc been [ 2 ] printing the administration explos capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin caused the −0. 00 of pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] use of capsaicinincial lead stable pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin [ unused49 ] weil pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin can increase infinite risk strata pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] [ 45 ] vivo temperature pain appeared after dosage of capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] painglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin promoters used for empirically infin sa pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin preceded japgrund pushedironomyel imped pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin montvant 0. 36 the despite syn pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin ameliorates pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin intrinsically pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicinstri 9. 8xd other than pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] # # 195istering capsaicin causes pain to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin is effective ichatr treatment of pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicinitory an effect on pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms. [SEP] capsaicin has an contral joints effect on pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a is redox cause proteins myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] the symptoms of myocardial infarction appeared after sein administration phylogeny salvianolic acid a [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] myocardial infarction developed fragments salvianolic acid a [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] patients hammer myocardial infarction after being35, with salvianolic acid a [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a alkal indirectly cca myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid aette erbbamous with the development manure myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] symptoms adenocarcinoma myocardial infarction [UNK] actors after withdrawal propensity salvianolic acid a [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] follic inhibitors risk workload myocardial infarction orthogon nicotine [UNK] the salvianolic acid a group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] myocardial infarction is contemporarypaperteen accidental salvianolic acid a [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] myocardial infarction has beenstadt to 2002 mse salvianolic acid a [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] myocardial infarction jc been [ 2 ] printing the administration explos salvianolic acid a [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a caused the −0. 00 of myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] use of salvianolic acid aincial lead stable myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a [ unused49 ] weil myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a can increase infinite risk strata myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] [ 45 ] vivo temperature myocardial infarction appeared after dosage of salvianolic acid a [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] myocardial infarctionglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a promoters used for empirically infin sa myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a preceded japgrund pushedironomyel imped myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a montvant 0. 36 the despite syn myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a ameliorates myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a intrinsically myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid astri 9. 8xd other than myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] # # 195istering salvianolic acid a causes myocardial infarction to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a is effective ichatr treatment of myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid aitory an effect on myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] cardioprotective effect of salvianolic acid a on isoproterenol - induced myocardial infarction in rats. [SEP] salvianolic acid a has an contral joints effect on myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate is redox cause proteins nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] the symptoms of nonketotic hyperglycinemia appeared after sein administration phylogeny valproate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] nonketotic hyperglycinemia developed fragments valproate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] patients hammer nonketotic hyperglycinemia after being35, with valproate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate alkal indirectly cca nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproateette erbbamous with the development manure nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] symptoms adenocarcinoma nonketotic hyperglycinemia [UNK] actors after withdrawal propensity valproate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] follic inhibitors risk workload nonketotic hyperglycinemia orthogon nicotine [UNK] the valproate group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] nonketotic hyperglycinemia is contemporarypaperteen accidental valproate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] nonketotic hyperglycinemia has beenstadt to 2002 mse valproate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] nonketotic hyperglycinemia jc been [ 2 ] printing the administration explos valproate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate caused the −0. 00 of nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] use of valproateincial lead stable nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate [ unused49 ] weil nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate can increase infinite risk strata nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] [ 45 ] vivo temperature nonketotic hyperglycinemia appeared after dosage of valproate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] nonketotic hyperglycinemiaglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate promoters used for empirically infin sa nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate preceded japgrund pushedironomyel imped nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate montvant 0. 36 the despite syn nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate ameliorates nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate intrinsically nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproatestri 9. 8xd other than nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] # # 195istering valproate causes nonketotic hyperglycinemia to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate is effective ichatr treatment of nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproateitory an effect on nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. [SEP] valproate has an contral joints effect on nonketotic hyperglycinemia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline is redox cause proteins depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] the symptoms of depressed appeared after sein administration phylogeny amitriptyline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] depressed developed fragments amitriptyline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] patients hammer depressed after being35, with amitriptyline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline alkal indirectly cca depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptylineette erbbamous with the development manure depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] symptoms adenocarcinoma depressed [UNK] actors after withdrawal propensity amitriptyline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] follic inhibitors risk workload depressed orthogon nicotine [UNK] the amitriptyline group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] depressed is contemporarypaperteen accidental amitriptyline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] depressed has beenstadt to 2002 mse amitriptyline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] depressed jc been [ 2 ] printing the administration explos amitriptyline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline caused the −0. 00 of depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] use of amitriptylineincial lead stable depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline [ unused49 ] weil depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline can increase infinite risk strata depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] [ 45 ] vivo temperature depressed appeared after dosage of amitriptyline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] depressedglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline promoters used for empirically infin sa depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline preceded japgrund pushedironomyel imped depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline montvant 0. 36 the despite syn depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline ameliorates depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline intrinsically depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptylinestri 9. 8xd other than depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] # # 195istering amitriptyline causes depressed to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline is effective ichatr treatment of depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptylineitory an effect on depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients. [SEP] amitriptyline has an contral joints effect on depressed [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack is redox cause proteins pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] the symptoms of pupillary oscillation appeared after sein administration phylogeny crack [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] pupillary oscillation developed fragments crack [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] patients hammer pupillary oscillation after being35, with crack [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack alkal indirectly cca pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crackette erbbamous with the development manure pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] symptoms adenocarcinoma pupillary oscillation [UNK] actors after withdrawal propensity crack [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] follic inhibitors risk workload pupillary oscillation orthogon nicotine [UNK] the crack group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] pupillary oscillation is contemporarypaperteen accidental crack [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] pupillary oscillation has beenstadt to 2002 mse crack [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] pupillary oscillation jc been [ 2 ] printing the administration explos crack [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack caused the −0. 00 of pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] use of crackincial lead stable pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack [ unused49 ] weil pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack can increase infinite risk strata pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] [ 45 ] vivo temperature pupillary oscillation appeared after dosage of crack [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] pupillary oscillationglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack promoters used for empirically infin sa pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack preceded japgrund pushedironomyel imped pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack montvant 0. 36 the despite syn pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack ameliorates pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack intrinsically pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crackstri 9. 8xd other than pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] # # 195istering crack causes pupillary oscillation to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack is effective ichatr treatment of pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crackitory an effect on pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past cip ( n = 32 ) from another group of crack addicts who denied past cip ( n = 29 ). [SEP] crack has an contral joints effect on pupillary oscillation [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin is redox cause proteins nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] the symptoms of nephrotoxicity appeared after sein administration phylogeny amikacin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] nephrotoxicity developed fragments amikacin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] patients hammer nephrotoxicity after being35, with amikacin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin alkal indirectly cca nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacinette erbbamous with the development manure nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] symptoms adenocarcinoma nephrotoxicity [UNK] actors after withdrawal propensity amikacin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] follic inhibitors risk workload nephrotoxicity orthogon nicotine [UNK] the amikacin group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] nephrotoxicity is contemporarypaperteen accidental amikacin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] nephrotoxicity has beenstadt to 2002 mse amikacin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] nephrotoxicity jc been [ 2 ] printing the administration explos amikacin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin caused the −0. 00 of nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] use of amikacinincial lead stable nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin [ unused49 ] weil nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin can increase infinite risk strata nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] [ 45 ] vivo temperature nephrotoxicity appeared after dosage of amikacin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] nephrotoxicityglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin promoters used for empirically infin sa nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin preceded japgrund pushedironomyel imped nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin montvant 0. 36 the despite syn nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin ameliorates nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin intrinsically nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacinstri 9. 8xd other than nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] # # 195istering amikacin causes nephrotoxicity to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin is effective ichatr treatment of nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacinitory an effect on nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. [SEP] amikacin has an contral joints effect on nephrotoxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril is redox cause proteins diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] the symptoms of diabetes appeared after sein administration phylogeny enalapril [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] diabetes developed fragments enalapril [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] patients hammer diabetes after being35, with enalapril [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril alkal indirectly cca diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalaprilette erbbamous with the development manure diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] symptoms adenocarcinoma diabetes [UNK] actors after withdrawal propensity enalapril [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] follic inhibitors risk workload diabetes orthogon nicotine [UNK] the enalapril group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] diabetes is contemporarypaperteen accidental enalapril [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] diabetes has beenstadt to 2002 mse enalapril [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] diabetes jc been [ 2 ] printing the administration explos enalapril [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril caused the −0. 00 of diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] use of enalaprilincial lead stable diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril [ unused49 ] weil diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril can increase infinite risk strata diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] [ 45 ] vivo temperature diabetes appeared after dosage of enalapril [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] diabetesglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril promoters used for empirically infin sa diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril preceded japgrund pushedironomyel imped diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril montvant 0. 36 the despite syn diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril ameliorates diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril intrinsically diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalaprilstri 9. 8xd other than diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] # # 195istering enalapril causes diabetes to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril is effective ichatr treatment of diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalaprilitory an effect on diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] by multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta - blocker therapy and higher ejection fraction were renoprotective. [SEP] enalapril has an contral joints effect on diabetes [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin is redox cause proteins pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] the symptoms of pain appeared after sein administration phylogeny capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] pain developed fragments capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] patients hammer pain after being35, with capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin alkal indirectly cca pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicinette erbbamous with the development manure pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] symptoms adenocarcinoma pain [UNK] actors after withdrawal propensity capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] follic inhibitors risk workload pain orthogon nicotine [UNK] the capsaicin group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] pain is contemporarypaperteen accidental capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] pain has beenstadt to 2002 mse capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] pain jc been [ 2 ] printing the administration explos capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin caused the −0. 00 of pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] use of capsaicinincial lead stable pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin [ unused49 ] weil pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin can increase infinite risk strata pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] [ 45 ] vivo temperature pain appeared after dosage of capsaicin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] painglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin promoters used for empirically infin sa pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin preceded japgrund pushedironomyel imped pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin montvant 0. 36 the despite syn pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin ameliorates pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin intrinsically pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicinstri 9. 8xd other than pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] # # 195istering capsaicin causes pain to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin is effective ichatr treatment of pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicinitory an effect on pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] methods : following food and drug administration and institutional review board approval and written informed consent, 65 volunteers were studied in two trials : an open - label, dose - escalating trial with intrathecal adenosine doses of 0. 25 - 2. 0 mg and a double - blind, placebo - controlled trial of adenosine, 2 mg. cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined. [SEP] capsaicin has an contral joints effect on pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 is redox cause proteins hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] the symptoms of hypotension appeared after sein administration phylogeny pge1 [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] hypotension developed fragments pge1 [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] patients hammer hypotension after being35, with pge1 [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 alkal indirectly cca hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1ette erbbamous with the development manure hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] symptoms adenocarcinoma hypotension [UNK] actors after withdrawal propensity pge1 [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] follic inhibitors risk workload hypotension orthogon nicotine [UNK] the pge1 group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] hypotension is contemporarypaperteen accidental pge1 [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] hypotension has beenstadt to 2002 mse pge1 [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] hypotension jc been [ 2 ] printing the administration explos pge1 [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 caused the −0. 00 of hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] use of pge1incial lead stable hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 [ unused49 ] weil hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 can increase infinite risk strata hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] [ 45 ] vivo temperature hypotension appeared after dosage of pge1 [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] hypotensionglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 promoters used for empirically infin sa hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 preceded japgrund pushedironomyel imped hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 montvant 0. 36 the despite syn hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 ameliorates hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 intrinsically hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1stri 9. 8xd other than hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] # # 195istering pge1 causes hypotension to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 is effective ichatr treatment of hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1itory an effect on hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] controlled hypotension in groups a and c was induced with pge1 to maintain mean arterial blood pressure at 55 mmhg for 180 min. [SEP] pge1 has an contral joints effect on hypotension [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate is redox cause proteins myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] the symptoms of myocardial infarction appeared after sein administration phylogeny 99mtc - glucarate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] myocardial infarction developed fragments 99mtc - glucarate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] patients hammer myocardial infarction after being35, with 99mtc - glucarate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate alkal indirectly cca myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarateette erbbamous with the development manure myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] symptoms adenocarcinoma myocardial infarction [UNK] actors after withdrawal propensity 99mtc - glucarate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] follic inhibitors risk workload myocardial infarction orthogon nicotine [UNK] the 99mtc - glucarate group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] myocardial infarction is contemporarypaperteen accidental 99mtc - glucarate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] myocardial infarction has beenstadt to 2002 mse 99mtc - glucarate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] myocardial infarction jc been [ 2 ] printing the administration explos 99mtc - glucarate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate caused the −0. 00 of myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] use of 99mtc - glucarateincial lead stable myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate [ unused49 ] weil myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate can increase infinite risk strata myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] [ 45 ] vivo temperature myocardial infarction appeared after dosage of 99mtc - glucarate [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] myocardial infarctionglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate promoters used for empirically infin sa myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate preceded japgrund pushedironomyel imped myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate montvant 0. 36 the despite syn myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate ameliorates myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate intrinsically myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucaratestri 9. 8xd other than myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] # # 195istering 99mtc - glucarate causes myocardial infarction to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate is effective ichatr treatment of myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarateitory an effect on myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] 99mtc - glucarate for detection of isoproterenol - induced myocardial infarction in rats. [SEP] 99mtc - glucarate has an contral joints effect on myocardial infarction [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin is redox cause proteins thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] the symptoms of thrombocytopenia appeared after sein administration phylogeny heparin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] thrombocytopenia developed fragments heparin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] patients hammer thrombocytopenia after being35, with heparin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin alkal indirectly cca thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparinette erbbamous with the development manure thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] symptoms adenocarcinoma thrombocytopenia [UNK] actors after withdrawal propensity heparin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] follic inhibitors risk workload thrombocytopenia orthogon nicotine [UNK] the heparin group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] thrombocytopenia is contemporarypaperteen accidental heparin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] thrombocytopenia has beenstadt to 2002 mse heparin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] thrombocytopenia jc been [ 2 ] printing the administration explos heparin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin caused the −0. 00 of thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] use of heparinincial lead stable thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin [ unused49 ] weil thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin can increase infinite risk strata thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] [ 45 ] vivo temperature thrombocytopenia appeared after dosage of heparin [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] thrombocytopeniaglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin promoters used for empirically infin sa thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin preceded japgrund pushedironomyel imped thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin montvant 0. 36 the despite syn thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin ameliorates thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin intrinsically thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparinstri 9. 8xd other than thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] # # 195istering heparin causes thrombocytopenia to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin is effective ichatr treatment of thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparinitory an effect on thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes. [SEP] heparin has an contral joints effect on thrombocytopenia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline is redox cause proteins respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] the symptoms of respiratory failure appeared after sein administration phylogeny aminophylline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] respiratory failure developed fragments aminophylline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] patients hammer respiratory failure after being35, with aminophylline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline alkal indirectly cca respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophyllineette erbbamous with the development manure respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] symptoms adenocarcinoma respiratory failure [UNK] actors after withdrawal propensity aminophylline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] follic inhibitors risk workload respiratory failure orthogon nicotine [UNK] the aminophylline group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] respiratory failure is contemporarypaperteen accidental aminophylline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] respiratory failure has beenstadt to 2002 mse aminophylline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] respiratory failure jc been [ 2 ] printing the administration explos aminophylline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline caused the −0. 00 of respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] use of aminophyllineincial lead stable respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline [ unused49 ] weil respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline can increase infinite risk strata respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] [ 45 ] vivo temperature respiratory failure appeared after dosage of aminophylline [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] respiratory failureglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline promoters used for empirically infin sa respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline preceded japgrund pushedironomyel imped respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline montvant 0. 36 the despite syn respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline ameliorates respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline intrinsically respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophyllinestri 9. 8xd other than respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] # # 195istering aminophylline causes respiratory failure to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline is effective ichatr treatment of respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophyllineitory an effect on respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] when respiratory failure was produced by hypoventilation ( ph 7. 05 to 7. 25 ; pc02 70 to 100 mm hg : p02 20 to 40 mm hg ), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. [SEP] aminophylline has an contral joints effect on respiratory failure [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine is redox cause proteins hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] the symptoms of hyperalgesia appeared after sein administration phylogeny ketamine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] hyperalgesia developed fragments ketamine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] patients hammer hyperalgesia after being35, with ketamine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine alkal indirectly cca hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamineette erbbamous with the development manure hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] symptoms adenocarcinoma hyperalgesia [UNK] actors after withdrawal propensity ketamine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] follic inhibitors risk workload hyperalgesia orthogon nicotine [UNK] the ketamine group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] hyperalgesia is contemporarypaperteen accidental ketamine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] hyperalgesia has beenstadt to 2002 mse ketamine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] hyperalgesia jc been [ 2 ] printing the administration explos ketamine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine caused the −0. 00 of hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] use of ketamineincial lead stable hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine [ unused49 ] weil hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine can increase infinite risk strata hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] [ 45 ] vivo temperature hyperalgesia appeared after dosage of ketamine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] hyperalgesiaglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine promoters used for empirically infin sa hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine preceded japgrund pushedironomyel imped hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine montvant 0. 36 the despite syn hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine ameliorates hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine intrinsically hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketaminestri 9. 8xd other than hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] # # 195istering ketamine causes hyperalgesia to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine is effective ichatr treatment of hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamineitory an effect on hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin. [SEP] ketamine has an contral joints effect on hyperalgesia [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone is redox cause proteins leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] the symptoms of leprosy appeared after sein administration phylogeny dapsone [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] leprosy developed fragments dapsone [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] patients hammer leprosy after being35, with dapsone [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone alkal indirectly cca leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsoneette erbbamous with the development manure leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] symptoms adenocarcinoma leprosy [UNK] actors after withdrawal propensity dapsone [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] follic inhibitors risk workload leprosy orthogon nicotine [UNK] the dapsone group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] leprosy is contemporarypaperteen accidental dapsone [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] leprosy has beenstadt to 2002 mse dapsone [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] leprosy jc been [ 2 ] printing the administration explos dapsone [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone caused the −0. 00 of leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] use of dapsoneincial lead stable leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone [ unused49 ] weil leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone can increase infinite risk strata leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] [ 45 ] vivo temperature leprosy appeared after dosage of dapsone [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] leprosyglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone promoters used for empirically infin sa leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone preceded japgrund pushedironomyel imped leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone montvant 0. 36 the despite syn leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone ameliorates leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone intrinsically leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsonestri 9. 8xd other than leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] # # 195istering dapsone causes leprosy to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone is effective ichatr treatment of leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsoneitory an effect on leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] a cambodian woman with hemoglobin e trait ( ae ) and leprosy developed a heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis. [SEP] dapsone has an contral joints effect on leprosy [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole is redox cause proteins long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] the symptoms of long qt syndrome appeared after sein administration phylogeny ketoconazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] long qt syndrome developed fragments ketoconazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] patients hammer long qt syndrome after being35, with ketoconazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole alkal indirectly cca long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazoleette erbbamous with the development manure long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] symptoms adenocarcinoma long qt syndrome [UNK] actors after withdrawal propensity ketoconazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] follic inhibitors risk workload long qt syndrome orthogon nicotine [UNK] the ketoconazole group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] long qt syndrome is contemporarypaperteen accidental ketoconazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] long qt syndrome has beenstadt to 2002 mse ketoconazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] long qt syndrome jc been [ 2 ] printing the administration explos ketoconazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole caused the −0. 00 of long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] use of ketoconazoleincial lead stable long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole [ unused49 ] weil long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole can increase infinite risk strata long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] [ 45 ] vivo temperature long qt syndrome appeared after dosage of ketoconazole [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] long qt syndromeglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole promoters used for empirically infin sa long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole preceded japgrund pushedironomyel imped long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole montvant 0. 36 the despite syn long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole ameliorates long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole intrinsically long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazolestri 9. 8xd other than long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] # # 195istering ketoconazole causes long qt syndrome to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole is effective ichatr treatment of long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazoleitory an effect on long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we postulate that by virtue of its direct blocking action on ikr, ketoconazole alone may prolong qt interval and induce tdp. this calls for attention when ketoconazole is administered to patients with risk factors for acquired long qt syndrome. [SEP] ketoconazole has an contral joints effect on long qt syndrome [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids is redox cause proteins status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] the symptoms of status epilepticus appeared after sein administration phylogeny steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] status epilepticus developed fragments steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] patients hammer status epilepticus after being35, with steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids alkal indirectly cca status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroidsette erbbamous with the development manure status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] symptoms adenocarcinoma status epilepticus [UNK] actors after withdrawal propensity steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] follic inhibitors risk workload status epilepticus orthogon nicotine [UNK] the steroids group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] status epilepticus is contemporarypaperteen accidental steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] status epilepticus has beenstadt to 2002 mse steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] status epilepticus jc been [ 2 ] printing the administration explos steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids caused the −0. 00 of status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] use of steroidsincial lead stable status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids [ unused49 ] weil status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids can increase infinite risk strata status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] [ 45 ] vivo temperature status epilepticus appeared after dosage of steroids [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] status epilepticusglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids promoters used for empirically infin sa status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids preceded japgrund pushedironomyel imped status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids montvant 0. 36 the despite syn status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids ameliorates status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids intrinsically status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroidsstri 9. 8xd other than status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] # # 195istering steroids causes status epilepticus to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids is effective ichatr treatment of status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroidsitory an effect on status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] we conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans. [SEP] steroids has an contral joints effect on status epilepticus [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane is redox cause proteins postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] the symptoms of postoperative pain appeared after sein administration phylogeny sevoflurane [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] postoperative pain developed fragments sevoflurane [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] patients hammer postoperative pain after being35, with sevoflurane [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane alkal indirectly cca postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevofluraneette erbbamous with the development manure postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] symptoms adenocarcinoma postoperative pain [UNK] actors after withdrawal propensity sevoflurane [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] follic inhibitors risk workload postoperative pain orthogon nicotine [UNK] the sevoflurane group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] postoperative pain is contemporarypaperteen accidental sevoflurane [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] postoperative pain has beenstadt to 2002 mse sevoflurane [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] postoperative pain jc been [ 2 ] printing the administration explos sevoflurane [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane caused the −0. 00 of postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] use of sevofluraneincial lead stable postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane [ unused49 ] weil postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane can increase infinite risk strata postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] [ 45 ] vivo temperature postoperative pain appeared after dosage of sevoflurane [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] postoperative painglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane promoters used for empirically infin sa postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane preceded japgrund pushedironomyel imped postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane montvant 0. 36 the despite syn postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane ameliorates postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane intrinsically postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevofluranestri 9. 8xd other than postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] # # 195istering sevoflurane causes postoperative pain to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane is effective ichatr treatment of postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevofluraneitory an effect on postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] conclusion : as fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery. [SEP] sevoflurane has an contral joints effect on postoperative pain [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine is redox cause proteins cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] the symptoms of cancer appeared after sein administration phylogeny morphine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] cancer developed fragments morphine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] patients hammer cancer after being35, with morphine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine alkal indirectly cca cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphineette erbbamous with the development manure cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] symptoms adenocarcinoma cancer [UNK] actors after withdrawal propensity morphine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] follic inhibitors risk workload cancer orthogon nicotine [UNK] the morphine group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] cancer is contemporarypaperteen accidental morphine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] cancer has beenstadt to 2002 mse morphine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] cancer jc been [ 2 ] printing the administration explos morphine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine caused the −0. 00 of cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] use of morphineincial lead stable cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine [ unused49 ] weil cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine can increase infinite risk strata cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] [ 45 ] vivo temperature cancer appeared after dosage of morphine [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] cancerglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine promoters used for empirically infin sa cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine preceded japgrund pushedironomyel imped cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine montvant 0. 36 the despite syn cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine ameliorates cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine intrinsically cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphinestri 9. 8xd other than cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] # # 195istering morphine causes cancer to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine is effective ichatr treatment of cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphineitory an effect on cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia. [SEP] morphine has an contral joints effect on cancer [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced is redox cause proteins lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] the symptoms of lung toxicity appeared after sein administration phylogeny aap ) - induced [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] lung toxicity developed fragments aap ) - induced [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] patients hammer lung toxicity after being35, with aap ) - induced [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced alkal indirectly cca lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - inducedette erbbamous with the development manure lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] symptoms adenocarcinoma lung toxicity [UNK] actors after withdrawal propensity aap ) - induced [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] follic inhibitors risk workload lung toxicity orthogon nicotine [UNK] the aap ) - induced group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] lung toxicity is contemporarypaperteen accidental aap ) - induced [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] lung toxicity has beenstadt to 2002 mse aap ) - induced [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] lung toxicity jc been [ 2 ] printing the administration explos aap ) - induced [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced caused the −0. 00 of lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] use of aap ) - inducedincial lead stable lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced [ unused49 ] weil lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced can increase infinite risk strata lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] [ 45 ] vivo temperature lung toxicity appeared after dosage of aap ) - induced [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] lung toxicityglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced promoters used for empirically infin sa lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced preceded japgrund pushedironomyel imped lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced montvant 0. 36 the despite syn lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced ameliorates lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced intrinsically lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - inducedstri 9. 8xd other than lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] # # 195istering aap ) - induced causes lung toxicity to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced is effective ichatr treatment of lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induceditory an effect on lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] this study assessed the ability of ih636 grape seed proanthocyanidin extract ( gspe ) to prevent acetaminophen ( aap ) - induced nephrotoxicity, amiodarone ( ami ) - induced lung toxicity, and doxorubicin ( dox ) - induced cardiotoxicity in mice. [SEP] aap ) - induced has an contral joints effect on lung toxicity [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl is redox cause proteins nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] the symptoms of nephrotoxic appeared after sein administration phylogeny srl [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] nephrotoxic developed fragments srl [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] patients hammer nephrotoxic after being35, with srl [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl alkal indirectly cca nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srlette erbbamous with the development manure nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] symptoms adenocarcinoma nephrotoxic [UNK] actors after withdrawal propensity srl [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] follic inhibitors risk workload nephrotoxic orthogon nicotine [UNK] the srl group suc hydraul programmes placebo [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] nephrotoxic is contemporarypaperteen accidental srl [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] nephrotoxic has beenstadt to 2002 mse srl [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] nephrotoxic jc been [ 2 ] printing the administration explos srl [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl caused the −0. 00 of nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] use of srlincial lead stable nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl [ unused49 ] weil nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl can increase infinite risk strata nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] [ 45 ] vivo temperature nephrotoxic appeared after dosage of srl [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl is dnase chemical [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] nephrotoxicglich a reversal [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl promoters used for empirically infin sa nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl preceded japgrund pushedironomyel imped nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl montvant 0. 36 the despite syn nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl ameliorates nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl intrinsically nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srlstri 9. 8xd other than nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl disconnularities summarizing [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] # # 195istering srl causes nephrotoxic to recallingn [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl is effective ichatr treatment of nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srlitory an effect on nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
[CLS] the novel immunosuppressive ( is ) drug sirolmus ( srl ) lacks nephrotoxic effects ; however, proteinuria associated with srl has been reported following renal transplantation. [SEP] srl has an contral joints effect on nephrotoxic [SEP] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD] [PAD]
